ABSTRACT
Heparin-induced thrombocytopenia (HIT) is a clinical syndrome that can cause both morbidity and mortality and is diagnosed by a combination of clinical and laboratory criteria. 1 The pathophysiology of the disorder involves activation of platelets by immune complexes containing antibodies to a complex composed of heparin and the platelet alpha granule protein, platelet factor 4 (PF4). A variety of immunoassays for quantifying these antibodies has been developed over the years. 2 The antibodies detected by these assays, however, differ in their ability to form platelet-activating immune complexes in the presence of heparin and PF4, 3 and it has been recognized for some time 4, 5 that many positive immunoassay results are false positives. Clinical scoring systems have been developed to assist in the diagnosis of HIT, 6, 7 but many view the demonstration that the patient's plasma has antibodies capable of activating platelets in the presence of heparin as the optimal way to diagnose the syndrome. The best-studied test of platelet activation in this setting is the washed platelet serotonin release assay (SRA). 8 The test is technically complex and uses a radiolabeled compound and therefore is currently performed only in reference laboratories. This makes SRA testing expensive for individual laboratories and results in a prolonged turnaround time (TAT).
The first generation of commercially available reagents to detect HIT antibodies detected antibodies belonging to the immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) classes. With further study, it was determined that most platelet-activating antibodies were of the IgG class due to the direct platelet activation by Fcγ receptor for IgG (FcγRIIA). Thus, a second generation of IgG-specific immunoassays © American Society for Clinical Pathology AJCP / Original article was introduced into clinical practice. 2 Since the probability of a confirmatory platelet activation assay (or an adjudicated clinical diagnosis of HIT) goes up with the degree of positivity of a HIT immunoassay, 4,5 laboratories have been advised to report the optical density (OD) values obtained by these assays to assist clinicians in their interpretation of a "positive" test. It is uncertain, however, whether IgG-specific HIT immunoassays eliminate the false positives associated with the first-generation (polytypic) tests in routine practice, thereby freeing laboratories of the need to report the degree of positivity of the test (as denoted by the OD).
Prior to the introduction of IgG-specific HIT testing in our laboratory, we instituted reflex SRA testing for all samples with a positive HIT immunoassay, defined as an OD of more than 0.4. Our rationale was based on the high false-positive rate of the polytypic assay. We hypothesized that the additional expense of SRA testing would be offset by the decreased utilization of the expensive direct thrombin inhibitors (DTIs) used to treat patients with HIT should the SRA result not confirm the presence of HIT. Within 16 months of starting this program, our laboratory switched to an IgG-specific HIT immunoassay. We continued our reflex SRA policy after this change. We report here our findings regarding (1) the relationship between the OD of the IgG-specific HIT immunoassay and the incidence of positive SRAs and (2) our assessment of the economic impact of this reflex testing policy.
Materials and Methods

Testing Method
The polytypic (IgG, IgA, IgM) PF4/heparin immunoassay testing was performed according to the manufacturer's instructions (LIFECODES PF4 Enhanced assay; Immucor, Norcross, GA). Likewise, the IgG-specific immunoassay testing was performed according to package inserts (LIFECODES PF4 IgG assay; Immucor). All samples with an immunoassay OD of 0.4 or greater were sent for SRA testing to the Blood Center of Wisconsin (Milwaukee, WI).
ODs between 0.4 and 0.99 were classified as low positives, those between 1.0 and 1.99 as intermediate positives, and 2.0 or more as high positives.
Data Analysis
We used our clinical laboratory data warehouse to identify patients who had SRA testing performed between April 2013 (when IgG-specific immunoassay testing was instituted) and November 2014. The query results were then transferred to a spreadsheet, and clinical data were obtained from the laboratory information system as well as the electronic medical record (EMR) using an institutional review board-approved protocol to calculate a 4Ts score for each patient and determine anticoagulant use after the performance of the SRA. We also reviewed the results obtained from our reflex SRA testing policy performed during the 16 months prior to the institution of IgG-specific HIT immunoassay testing, when a polytypic HIT immunoassay was in use. After all data were obtained, we stratified the patients into low, intermediate, and high OD categories based on the IgG-specific PF4/ heparin immunoassay OD result. We also correlated the SRA percent release result with the immunoassay OD result.
A 4Ts score was calculated for each individual patient based on data extracted from the EMR, using the method of Lo et al. 6 The 4Ts scores were compared for statistical significance using the Student t test. A more than 20% serotonin release result on the SRA was considered the gold standard for diagnosing HIT. We then constructed receiver operator characteristic (ROC) curves. Statistical analyses were performed using MedCalc for Windows, version 15.0 (MedCalc Software, Ostend, Belgium). The software derives the optimized cutoffs to maximize the area under the ROC curve and the corresponding sensitivities and specificities.
Chart review was performed to determine the impact of a negative SRA result on DTI utilization. Neither the hospital laboratory nor pharmacy called or otherwise notified physicians of the results of SRA testing. For purposes of our analysis, we assumed that a patient treated with an unfractionated heparin infusion after the return of a negative SRA would have instead been continued on a parenteral DTI had the SRA not been performed. To determine the medication costs avoided due to the negative SRA results, we calculated the total number of days of inpatient anticoagulation with unfractionated heparin such patients received after the return of a negative SRA result. Patients were considered to have avoided DTI therapy only if they had previously been treated with a DTI during the admission and pharmacotherapy had been transitioned to a heparin product after the SRA result was documented. We then estimated the costs of continuing a patient's argatroban or bivalirudin therapy for the same duration of time, using calculations similar to those used in a recent cost analysis. 9 As was assumed in the recent analysis, we used hypothetical dosage rates of 0.05 μg/ kg/min for argatroban and 0.15 mg/kg/h for bivalirudin. Actual patient dosing weights were used, as was the
© American Society for Clinical Pathology
Vanderbilt et al / Reflex SRA TeSTing foR HiT lowest currently listed average wholesale price (AWP) of each medication. 10 We did not account for drug waste in our analysis. We subtracted from the DTI costs the AWP of the actual dispensed quantity of unfractionated heparin products used. Only medication costs were used in this analysis; other costs related to drug monitoring and labor were not considered.
Results
Relationship Between Positive IgG HIT Immunoassay Results and SRA Results
Seventy-seven SRA results, obtained from 76 patients, were identified in the 18 months following the institution of IgG HIT immunoassay testing in our institution. A duplicate test from one patient was excluded, as was one SRA result that was performed on a patient with a negative IgG HIT immunoassay, resulting in a total of 75 included samples.
The OD obtained in the IgG-specific PF4/heparin immunoassay was plotted against the amount of radioactive serotonin released in the presence of low-dose heparin, as shown in ❚Figure 1❚. A positive SRA (defined by the reference laboratory as a low-dose heparin-induced serotonin release of 20%, high dose <20%) was found in 32 (43%) of 75 samples. These results are similar to a recent report from a reference laboratory where 1,111 (38%) of 2,918 samples tested with an in-house IgG-specific immunoassay had an OD of more than 0.45 and were positive in the SRA.
11
Comparison of Polytypic and IgG-Specific HIT Immunoassays
We analyzed the incidence of positive SRAs during the 16 prior months when our laboratory reported results of a polyspecific HIT immunoassay. Our observations were very similar to others 5 who found that the likelihood of a positive SRA went up as a function of the OD of the polytypic immunoassay. We found a similar relationship was present when the IgG-specific immunoassay was used instead of the polytypic assay ❚Table 1❚. In fact, the percentage of samples with positive SRA results was remarkably similar when OD measurements were used to classify positive immunoassays as low (0.4-0.99), intermediate (1-1.99), or high (≥2.0). This finding indicates that laboratories should report to clinicians the OD of the IgGspecific HIT immunoassay, as they have for the polytypic assays.
4TS Clinical Score
Sufficient clinical data were available to calculate the 4Ts clinical score for 51 (67%) of the 76 patients. The 4Ts clinical scores were statistically different between high-positive and low-positive IgG HIT immunoassay patients (mean for low positives, 2.53; mean for high positives, 4.93; P = .0035). A statistically significant 4Ts score difference was also seen when comparing positive to negative SRA results (mean for negative SRA, 2.81; mean for positive SRA, 5.04; P < .001). The 4Ts scores did show a general trend toward higher scores with both higher ODs and higher SRA values; the power of this correlation was not obvious by naive analysis ❚Figure 2A❚ and ❚Figure 2B❚.
ROC Curve Analysis
ROC curves were constructed using a positive SRA as the gold standard for a diagnosis of HIT ❚Figure 3A❚ and ❚Figure 3B❚. Our analysis determined that the optimal OD cutoff for the IgG immunoassay test to be 0.59, which resulted in a sensitivity of 96% and a specificity of 63%. In comparison, use of the 4Ts clinical score alone identified a score of more than 3 as the optimal cutoff, resulting in a sensitivity of 83.3% and a specificity of 63%. Noting that both clinical 4Ts score and immunoassay OD have a nonrandom association with SRA results, we attempted to empirically determine an optimal combination of the two (using both linear and logarithmic variations). We experimented with various combinations of the OD and 4Ts score to see if combining these metrics could result in improved prediction of a positive SRA. We were able to achieve a 100% sensitivity with our data by algorithmically combining OD and 4Ts data points. Experimenting ❚Figure 1❚ Distribution of percent release of serotonin with low-dose heparin in serotonin-release assay as a function of optical density of immunoglobulin G-specific heparin-induced thrombocytopenia immunoassay.
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AJCP / Original article with various combinations of the two variables, we were able to create an optimal algorithm: OD + (4Ts score × 10%). Despite the improvement in sensitivity by this method, the area under the ROC curve changed little and the specificity remained less than 70% ❚Figure 3C❚ and ❚Table 2❚.
Characteristics of Patients With Discordant HIT Testing Results
The clinical records of patients that failed to show correlation between OD and SRA percent release were examined in some detail. The patients with low/ Figure 1 ) by immunoassay testing if a higher immunoassay OD was used as the sole determinant of DTI use, while patients with high immunoassay OD and negative SRA would be considered "false positives" under this paradigm (data points in upper left in Figure 1 ). The "false negatives" in our study all had relatively high average 4Ts clinical scores (mean of 5.67 out of a possible total of 8), while the "false positives" had average 4Ts clinical scores that were lower (mean, 4.9). Investigation of the clinical characteristics of these patients showed that all "false positives" (10 of 10) presented with conditions associated with high amounts of tissue destruction (ie, trauma, burns, cardiogenic shock, metastatic malignancy, and acute thrombosis). These results are reminiscent of previous observations 12 indicating that patient characteristics may play a major role in determining the frequency of "false-positive" HIT immunoassays. Also noted was the fact that a higher than expected fraction of the "false-positive" results was recorded in male patients. While males constituted 54% of all patients and 47% of the "true positives," they accounted for 70% of the "false-positive" patients.
Economic Impact of a Policy of SRA Reflex Testing
Most patients were treated with DTIs during the initial evaluation for HIT; in patients with negative SRA tests, DTI therapy was usually discontinued. In five patients, DTI therapy was stopped and patients were switched to unfractionated heparin for ongoing anticoagulation needs following return of a negative SRA test ❚Table 3❚. Assuming that DTI treatment would have continued for the same duration of time as the observed heparin treatment (if the SRA had not been sent), 34 days of anticoagulation with DTIs and $20,442 in medication costs were avoided. In addition, five patients with negative SRAs were hospitalized again within 2 months of discharge from the index hospitalization and treated with unfractionated heparin. Assuming that parenteral DTIs would have been used in place of heparin in these patients had HIT not been ruled out with a negative SRA during the index A B C ❚Figure 3❚ The receiver operator characteristic (ROC) curves for the metrics studied are shown. The curves were developed using the positive serotonin-release assay (percent release >20%, low dose) as the "gold standard. " Optimal cutoffs, along with specificity, sensitivity, and area under the curve, are summarized in Table 2 . A, ROC curve for immunoglobulin G-specific heparin-induced thrombocytopenia immunoassay optical density (OD). B, ROC curve for 4Ts clinical score. C, ROC curve, the optimized combination of 4Ts and OD, using both OD added to the 4Ts score multiplied by 10%: OD + (4Ts * 10%). hospitalization, another 44 days of anticoagulation with DTIs and a medication cost of $28,279 were avoided. The approximate total cost of SRA testing for the study period was $25,000, including the cost of testing as well as allotment for shipping cost and technical time required for sending material out and reporting results.
Discussion
We present here the findings from a 34-month period during which positive HIT immunoassay results were routinely followed up with SRA testing. We are unaware of publication of a similar program. The policy was initially instituted to provide optimal laboratory support for clinicians wrestling with the clinical problem of diagnosing and treating HIT. The rationale for this program was based on findings that a positive (polytypic) HIT immunoassay did not accurately identify patients with platelet-activating HIT antibodies by either serologic 5 or clinical 4 criteria. The high false-positive rate of the immunoassay was such that a reflex testing policy was thought to provide an opportunity to decrease utilization of the relatively expensive direct inhibitors that are used to treat patients with HIT, although at a greater expense for the laboratory.
After 16 months, the polytypic HIT immunoassay was dropped in favor of an IgG-specific HIT immunoassay. The latter was thought to be more specific, but it was not immediately obvious that a positive result would be sufficient to identify patients with high probabilities of having the syndrome of HIT, which is often made on the basis of a positive SRA. We have therefore analyzed the incidence of positive SRA results as a function of the degree of positivity of each of the immunoassays used in our institution during this time.
Many economic analyses related to laboratory testing only consider the cost of testing within the laboratory.
While these economic analyses are important in demonstrating better utilization of the laboratory 13, 14 and attendant cost savings, there are specific situations in which increased laboratory costs of testing may be justified by savings achieved in other departments. In the case of laboratory testing for HIT, both false-positive and false-negative results have enormous costs. False-positive results lead to the unnecessary use of expensive DTIs. [15] [16] [17] Falsenegative results can result in catastrophic thrombotic events with enormous financial impacts for patients, clinicians, and the institution as a whole. 18 It is natural to wish to minimize costs, and an approach allowing clinicians to determine when SRA testing should be performed might seem attractive to laboratorians. A recent report of an institution with such a policy indicated that the global cost of treating patients did not differ between patients who had an SRA performed and those who did not. 19 The experience in question differs significantly from the reflex testing policy we describe here, however, because the clinician-requested SRA testing resulted in the tests being performed at different time points during the hospitalization (likely in the more problematic patients). TATs in their study averaged over 1 week, and a faster TAT (ours is usually 3-4 days) might well have affected their findings. Thus, this report differs substantially from that of Sadik et al 19 and should not be directly compared by institutions contemplating reflex SRA testing.
By performing a chart review, we found that five patients were changed from a DTI to heparin after a negative SRA result was reported. In addition, we found that these patients were hospitalized five times in aggregate (within 2 months) and treated with parenteral heparin. They would have likely received an alternative anticoagulant (likely more expensive than heparin) had the negative SRA result not been available. It is possible that the reduction in DTI costs we present here is only one source of cost savings realized via reflexive SRA testing. Even greater reductions in DTI use were likely realized as a result of reflex SRA testing, as DTIs were discontinued (without switching to an alternative anticoagulation such as heparin) in some patients with negative SRAs. These additional reductions in DTI use and other effects on costs are difficult to quantify without a comparator group. We also note that the increased safety of a heparin-based product with well-described, routine monitoring of therapeutic doses is not easily quantified but is an additional advantage of being able to transition patients off DTI therapy. Many published articles have contemplated the best way to manage patients who are clinically suspected of having HIT, including potentially raising the threshold for considering an PF4/heparin immunoassay positive 8 and/or combining OD measurements with clinical criteria, such as the 4Ts score. 20, 21 Our own attempts at incorporating clinical 4Ts with immunoassay OD shows that it is possible to achieve remarkable sensitivity but without improving specificity, using simple linear and logarithmic mathematics. Whether new methods of applying machine-learning algorithms (ie, support vector machines, naive Bayes, deep neural networks, etc) to laboratory and clinical data 22 will obviate the need for SRA testing remains to be determined. Our reflex testing policy does not require input from the clinical service, a practical consideration given expanding hospital networks that use central laboratories.
Limitations
Our retrospective study carries all the limitations of such analyses. Changing patterns of use of anticoagulant drugs and/or the costs of such drugs might well alter the results of a similar analysis performed in the future. Input from clinicians in real time would be necessary to accurately determine if such a policy affects the length of hospitalization, which could have major impacts on hospital costs. While our study is not definitive regarding effects on costs, it suggests that reflex SRA testing could be globally cost neutral or cost saving. We were not able to analyze patient records adequately to determine if additional savings might occur if the laboratory and the pharmacy were to work together in curtailing use of DTIs once a negative SRA result was reported. Finally, we have not evaluated other clinical scoring systems that have been developed for diagnosing HIT, 7 which might be useful when combined with HIT immunoassay testing.
Conclusions
We have found through implementation of a policy of reflex SRA testing for samples that are positive using a commercially available IgG-specific HIT immunoassay that the likelihood of having a positive SRA varies with the OD of the immunoassay. Thus, we recommend that laboratories performing IgG-specific HIT immunoassays continue the policy of reporting the OD of the test results, just as they have with polytypic HIT immunoassays. We have found that the costs of a reflex SRA testing policy are minimal and are offset by changes in DTI administration and may well be cost saving for the institution. Efforts to increase communication and cooperation between laboratories and pharmacy services could likely lead to additional improvements in the care of patients suspected of having HIT.
